Co-Authors
This is a "connection" page, showing publications co-authored by JEAN NICOLAS VAUTHEY and EDMUND SCOTT KOPETZ.
Connection Strength
2.463
-
From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer. 2013 Dec 01; 119(23):4083-5.
Score: 0.461
-
Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008 Mar 22; 371(9617):963-5.
Score: 0.315
-
Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol. 2015 May; 22(5):1585-92.
Score: 0.125
-
Return to intended oncologic treatment (RIOT): a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014 Aug; 110(2):107-14.
Score: 0.121
-
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013 Oct; 258(4):619-26; discussion 626-7.
Score: 0.116
-
Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013 Jun; 257(6):1079-88.
Score: 0.113
-
Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012 Dec 20; 30(36):4566-72.
Score: 0.109
-
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50.
Score: 0.108
-
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92.
Score: 0.097
-
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90.
Score: 0.096
-
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010 Nov; 17(11):2870-6.
Score: 0.092
-
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55.
Score: 0.091
-
Sequenced chemotherapy and surgery for potentially resectable colorectal liver metastases: a debate over goals of research and an approach while the jury remains out. Ann Surg Oncol. 2010 Aug; 17(8):1983-6.
Score: 0.090
-
Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30.
Score: 0.088
-
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83.
Score: 0.085
-
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009 Mar; 16(3):614-22.
Score: 0.083
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.082
-
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol. 2014 Oct; 18(5):266-70.
Score: 0.031
-
Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer. 2013 Aug 01; 119(15):2778-88.
Score: 0.028
-
CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. AJR Am J Roentgenol. 2011 Dec; 197(6):W1060-6.
Score: 0.025
-
Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010 Sep; 34(9):1287-94.
Score: 0.023
-
Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010 Jun; 210(6):934-41.
Score: 0.023
-
Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009 Dec 02; 302(21):2338-44.
Score: 0.022
-
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008 Nov 10; 26(32):5254-60.
Score: 0.020
-
Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg. 2007 Nov; 11(11):1498-504; discussion 1504-5.
Score: 0.019